Therapy of obesity by sibutramin: polymorphisms of TPH2 and GNB3 genes and decrease of body weight
Marina O. Galieva,
Ekaterina A. Troshina,
Nataliya V. Mazurina,
Anna P. Volynkina,
Andrey V. Artiushin,
Anastasia S. Pavlova https://doi.org/10.14341/omet9646
Abstract
Aims. To study of the polymorphisms of the TPN2 and GNB3 genes in obese patients and their effect on weight loss in patients on sibutramine therapy.
Materials and methods. The research study included 118 patients with exogenous-constitutional obesity who received Reduxin (sibutramine + CMC) at the dose of 10 mg. Term follow-up was 3 months. A genetic study was performed to assess ТРН2 and GNB3 gene polymorphisms. The response to the therapy was evaluated after 3 months by the dynamics of body weight.
Results. In the study the G703T polymorphism of the GNB3 gene showed that during 3 months of observation, carriers of the TT genotype had a greater decrease in body weight in comparison with carriers of the allele C – -8 kg (-12; -5) vs. -5 kg (-8; -3), p = 0.018. In carriers of different variants of the genotype of the TPH2 gene (polymorphism C825T), there was no difference in body weight dynamics with sibutramine therapy. There was no correlation between the foresaid polymorphisms of the TPH2 and GNB3 genes with the indices of blood pressure and heart rate.
Conclusions. 1. The result of sibutramin therapy may depend on genetic factors: in carriers of the TT-genotype C825T of the GNB3 gene the body weight loss was higher than among the carriers of the C allele. 2. Changes in blood pressure and heart rate did not show any statistically significant relationship with polymorphisms of the TPH2 and GNB3 genes.
About the Authors
Marina O. GalievaEndocrinology Research Centre
Russian Federation
postgraduate student
Ekaterina A. Troshina
Endocrinology Research Centre
Russian Federation
ScD, professor, correspondence fellow of RAS
Nataliya V. Mazurina
Endocrinology Research Centre
Russian Federation
PhD
Anna P. Volynkina
Voronezh State Medical University named after N.N. Burdenko
Russian Federation
PhD
Andrey V. Artiushin
Laboratory «LAGES»
Russian Federation
Anastasia S. Pavlova
Laboratory «LAGES»
Russian Federation
References
1. Best J, Nijhout HF, Reed M. Serotonin synthesis, release and reuptake in terminals: a mathematical model. Theoretical Biology and Medical Modelling. 2010;7(1):34. doi: 10.1186/1742-4682-7-34.
2. Lam DD, Garfield AS, Marston OJ, et al. Brain serotonin system in the coordination of food intake and body weight. Pharmacol. Biochem. Behav. 2010;97(1):84-91. doi: 10.1016/j.pbb.2010.09.003.
3. Garfield AS, Burke LK, Shaw J, et al. Distribution of cells responsive to 5-HT6 receptor antagonist-induced hypophagia. Behav. Brain Res. 2014;266:201-206. doi: 10.1016/j.bbr.2014.02.018.
4. Smith DG, Robbins TW. The Neurobiological Underpinnings of Obesity and Binge Eating: A Rationale for Adopting the Food Addiction Model. Biol. Psychiatry. 2013;73(9):804-810. doi: 10.1016/j.biopsych.2012.08.026.
5. Yeo GSH, Heisler LK. Unraveling the brain regulation of appetite: lessons from genetics. Nat. Neurosci.2012;15(10):1343-1349. doi: 10.1038/nn.3211.
6. Chen G-L, Vallender EJ, Miller GM. Functional characterization of the human TPH2 5' regulatory region: untranslated region and polymorphisms modulate gene expression in vitro. Hum. Genet.2007;122(6):645-657. doi: 10.1007/s00439-007-0443-y.
7. Hashimoto K, Latsko MS, Gilman TL, et al. A Novel Interaction between Tryptophan Hydroxylase 2 (TPH2) Gene Polymorphism (rs4570625) and BDNF Val66Met Predicts a High-Risk Emotional Phenotype in Healthy Subjects. PLoS One. 2016;11(10):e0162585. doi: 10.1371/journal.pone.0162585.
8. Han K-M, Won E, Kang J, et al. Local gyrification index in patients with major depressive disorder and its association with tryptophan hydroxylase-2 (TPH2) polymorphism. Hum. Brain Mapp.2017;38(3):1299-1310. doi: 10.1002/hbm.23455.
9. Porcelli S, Drago A, Fabbri C, et al. Pharmacogenetics of antidepressant response. J. Psychiatry Neurosci.2011;36(2):87-113. doi: 10.1503/jpn.100059.
10. Mandelli L, Antypa N, Nearchou FA, et al. The role of serotonergic genes and environmental stress on the development of depressive symptoms and neuroticism. J. Affect. Disord. 2012;142(1-3):82-89. doi: 10.1016/j.jad.2012.03.047.
11. de Erausquin GA, Gao J, Pan Z, et al. TPH2 Gene Polymorphisms and Major Depression – A Meta-Analysis. PLoS One. 2012;7(5):e36721. doi: 10.1371/journal.pone.0036721.
12. Su Y-A, Li J-T, Dai W-J, et al. Genetic variation in the tryptophan hydroxylase 2 gene moderates depressive symptom trajectories and remission over 8 weeks of escitalopram treatment. Int. Clin. Psychopharmacol. 2016;31(3):127-133. doi: 10.1097/yic.0000000000000115.
13. Tzvetkov MV, Brockmöller J, Roots I, Kirchheiner J. Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment. Pharmacogenet. Genomics.2008;18(6):495-506. doi: 10.1097/FPC.0b013e3282fb02cb.
14. Xu Z, Reynolds GP, Yuan Y, et al. TPH-2 Polymorphisms Interact with Early Life Stress to Influence Response to Treatment with Antidepressant Drugs. Int. J. Neuropsychopharmacol. 2016;19(11):pyw070. doi: 10.1093/ijnp/pyw070.
15. Chung KY, Rasmussen SGF, Liu T, et al. Conformational changes in the G protein Gs induced by the β2 adrenergic receptor. Nature. 2011;477(7366):611-615. doi: 10.1038/nature10488.
16. Zamponi GW, Currie KPM. Regulation of CaV2 calcium channels by G protein coupled receptors. Biochim. Biophys. Acta. 2013;1828(7):1629-1643. doi: 10.1016/j.bbamem.2012.10.004.
17. Danoviz ME, Pereira AC, Mill JG, Krieger JE. Hypertension, Obesity and Gnb3 Gene Variants. Clin. Exp. Pharmacol. Physiol. 2006;33(3):248-252. doi: 10.1111/j.1440-1681.2006.04353.x.
18. Siffert W, Forster P, Jockel KH, et al. Worldwide ethnic distribution of the G protein beta3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individuals. J. Am. Soc. Nephrol. 1999;10(9):1921-1930.
19. Keers R, Bonvicini C, Scassellati C, et al. Variation in GNB3 predicts response and adverse reactions to antidepressants. Psychopharm. 2010;25(7):867-874. doi: 10.1177/0269881110376683.
20. Дедов И.И., Трошина Е.А., Мазурина Н.В., и др. Роль нейротрансмиттеров в регуляции энергетического гомеостаза и возможности медикаментозной коррекции его нарушений при ожирении // Ожирение и метаболизм. – 2016. – Т.13. – №1 – С.9-15. [Dedov II, Troshina EA, Mazurina NV, et al. The role of neurotransmitters in regulation of energy homeostasis and possibility of drug correction of its disturbances in obesity. Obesity and metabolism. 2016;13(1):9-15. (In Russ).] doi: 10.14341/omet201619-15
21. Аметов А.С. Отчет о программе ВЕСНА. Эффективное лечение ожирения – путь борьбы с эпидемией Diabetus mellipidus // Эффективная фармакотерапия. Спецвыпуск. – 2013; – C. 7-11. [Ametov AS. Otchet o programme VESNA. Effektivnoe lechenie ozhireniya – put borbyi s epidemiey Diabetus mellipidus. Effektivnaya farmakoterapiya. Spetsvyipusk. 2013;7-11. (In Russ).].
22. Дедов И.И., Мельниченко Г.А., Романцова Т.И. Стратегия управления ожирением: итоги Всероссийской наблюдательной программы «ПримаВера» // Ожирение и метаболизм. – 2016; – Т. 13. – № 1. – С. 36-44. [Dedov II, Mel'nichenko GA, Romantsova TI. The strategy of obesity management: the results of All-Russian observational program "Primavera". Obesity and metabolism.2016;13(1):36-44. (In Russ).] doi: 10.14341/omet2016136-44
23. Sarwer DB, Lavery M, Spitzer JC. A review of the relationships be- tween extreme obesity, quality of life, and sexual function Obes Surg. 2012;22(4): 668. doi:10.1007/s11695-012-0588-1
24. F X Pi-Sunyer. Weight Loss and Mortality in Type 2 Diabetes. Diabetes Care. 2000;23(10):1451-1452; doi: 10.2337/diacare.23.10.1451
25. Hsiao D-J, Wu LS-H, Huang S-Y, Lin E. Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in the GNB3 gene. Pharmacogenet. Genomics. 2009;19(9):730-733. doi: 10.1097/FPC.0b013e3283307cf1.
26. Трошина Е.А., Мазурина Н.В., Галиева М.О. Создание стратегий лечения ожирения и коморбидных заболеваний на основе наблюдательных программ: промежуточные результаты всероссийской наблюдательной программы ПримаВера. Альманах клинической медицины. – 2015. – № S1. – С. 95-101. [Troshina E., Mazurina NV, Galieva MO. Development of therapeutic strategies for obesity and comorbid disorders based on observational programs: interim results of the Russian observational program PrimaVera. Almanac of Clinical Medicine. 2015;(S1):95-101. (In Russ).].
Review
For citations:
Galieva M.O., Troshina E.A., Mazurina N.V., Volynkina A.P., Artiushin A.V., Pavlova A.S. Therapy of obesity by sibutramin: polymorphisms of TPH2 and GNB3 genes and decrease of body weight. Obesity and metabolism. 2018;15(2):40-45. (In Russ.) https://doi.org/10.14341/omet9646
Views:
1098
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
